Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 2, keine Gesamtzahl für „Zelboraf“
Suchtreffer
Begriffe & Kennungen
Zelboraf · 4.5 · The effects of P-gp and BCRP inhibitors that are not also strong CYP3A4 inhibitors are unknown. It cannot be e
Eintrag öffnenZelboraf · 4.5 · The effects of vemurafenib on medicinal products that are substrates of BCRP are unknown. It cannot be exclude
Eintrag öffnenZelboraf · 4.5 · The possible effect of vemurafenib on other transporters is currently unknown.
Eintrag öffnenZelboraf · 4.5 · Vemurafenib moderately inhibited CYP2C8 in vitro. The in vivo relevance of this finding is unknown, but a risk
Eintrag öffnenZelboraf · 4.6 Fertility, pregnancy and lactation · 1
Eintrag öffnenZelboraf · 4.8 Undesirable effects · 1
Eintrag öffnenZelboraf · 4.8 · 10 Table 3: ADRs occurring in patients treated with vemurafenib in the phase II or phase III studyand events o
Eintrag öffnenZelboraf · 4.8 · 11 System organ class Very Common Common Uncommon Rare
Eintrag öffnenZelboraf · 4.8 · Acute kidney injury (h) Cases of renal toxicity have been reported with vemurafenib ranging from creatinine el
Eintrag öffnenZelboraf · 4.8 · Blood and lymphatic Neutropenia, system disorders thrombocytopenia (6)
Eintrag öffnenZelboraf · 4.8 · Dermatologic reactions (f) Severe dermatologic reactions have been reported in patients receiving vemurafenib,
Eintrag öffnenZelboraf · 4.8 · Description of selected adverse reactions
Eintrag öffnenZelboraf · 4.8 · Elderly In the phase III study, ninety-four (28%) of 336 patients with unresectable or metastatic melanoma tre
Eintrag öffnenZelboraf · 4.8 · Gender During clinical trials with vemurafenib, grade 3 adverse reactions reported more frequently in females
Eintrag öffnenZelboraf · 4.8 · Hepatic enzyme increase (c) Liver enzyme abnormalities reported in the phase III clinical study are expressed
Eintrag öffnenZelboraf · 4.8 · Hypersensitivity reactions (e) Serious hypersensitivity reactions, including anaphylaxis have been reported in
Eintrag öffnenZelboraf · 4.8 · Immune System Sarcoidosis(1)(2)(j) Disorders
Eintrag öffnenZelboraf · 4.8 · In a phase III clinical trial (MO25515, N= 3219), a higher incidence of potentiation of radiation toxicity was
Eintrag öffnenZelboraf · 4.8 · In this section, ADRs are based on results in 468 patients from a phase III randomised open label study in adu
Eintrag öffnenZelboraf · 4.8 · Infections and Folliculitis infestations Neoplasms benign, SCC of the skin(d), Basal cell Non-cuSCC(1)(3) Chro
Eintrag öffnen